Attorneys Analyze FDA’s Case Against Utah Medical, Impact On Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Deputy Chief Counsel Eric Blumberg says the agency will continue to prosecute firms with weak quality controls, even if there are no reports of safety problems.